Menu
Log In Sign Up
Article

p7c3 a20 peptide Research-grade P7c3 A20 Inhibitor

Published October Oct 18, 2026 3:56 AM

In the evolving field of neuro-scientific investigation, few compounds have garnered as much attention as P7C3-A20 peptide. As someone deeply invested in tracking advancements in cellular biochemistry and neuroprotective agents, I have spent considerable time analyzing the literature surrounding this fascinating aminopropyl carbazole. It is important to clarify that this information is intended strictly for research purposes; it does not constitute medical adv P7C3-A20 from Aladdin Scientific ice, and I do not advocate for human use of these compounds.

What is P7C3-A20?

At its core, P7C3-A20 is a highly active analogue of the original P7C3 molecule. It is widely recognized in laboratory s P7C3-A20 | NAMPT activator/Proneurogenic agent ettings as a potent neuroprotective agent. The chemical structure is designed to interact with nicotinamide phosphoribosyltransferase (NAMPT), an enzyme critical for the biosynthesis of NAD+. By acting as a NAMPT activator, the compound helps elevate cellular nicotinamide adenine dinucleotide (NAD+) levels, which are often depleted during periods of cellular stress or injury.

Key Research Findings and Mechanisms

The scientific community has documented seve The neuroprotective compound P7C3-A20 promotes ral impressive properties of this compound in various models. When evaluating the data, it becomes clear why researchers are so focused on its potential:

* Blood-Brain Barrier Integrity: One of the most compelling findings is that P7C3-A20 has been shown to repair the blood-brain barrier. This is a critical factor in maintaining neurological homeostasis.

* Neuroprotection and Neuron Survival: The compound actively fosters the survival of neurons. By acting as an anti-apoptotic agent, it prevents programmed cell death in sensitive hippocampal regions.

* Mitigation of Neurodegeneration: Extensive studies indicate that P7C3-A20 treatment mitigates neurodegeneration in various models, including those investigating focal ischemia and chronic injury.

* Behavioral Improvements: In preclinical models, P7C3-A20 treatment significantly improved behavioral outcomes, including memory and sensorimotor function, which translates into chronic behavioral improvement.

* Anti-Inflammatory Properties: Beyond direct neuronal support, P7C3-A20 treatment suppressed neuroinflammation Description. P7C3-A20, a derivative of P7C3, exhibits both proneurogenic and neuroprotective activities (brackets). ; Molecular Weight, 506.21 ; Formula, C22H19Br  and protected reti P7C3-A20 has been shown to repair the blood-brain barrier, arrests chronic neurodegeneration and restores cognition one year after TBI in a mouse model (3). In  nal Protein Analysis Reagents · Recombinant Proteins · Shop All Life Sciences P7C3-A20 | Purity: 98.96% | MW: 506.21 | 1235481-90-9 | MFCD28023591 | 5mg. ganglion cells, demonstrating a multifaceted approach to cellular health.

Observations on Cognitive and Pathological Models

Perhaps the most exciting area of study involves P7C3-A20 its role in age-related cognitive decline. Recent data suggests that the molecule is able to reverse the brain pathology and cognitive decline in specific mouse models. Researchers have observed that it reduces microtubule-associated protein 1 light chain 3-II (LC3-II) levels, which is a marker often associated with autophagy-related processes in the brain.

Furthermore, because P7C3-A20 exerts an antidepressant-like effect and exerts antidepressant efficacy in mice, it is currently being scrutinized for its ability to enhance P7C3-A20 | CAS 1235481-90-9 - Selleck Chemicals hippocampal neurogenesis. These findings are supported by evidence that it safely protects neurons in nonhuman primates, suggesting a robust profile that warrants further investigation.

Understanding the Research-Grade Context

When navigating the landscape of research chemicals, it is common to encounter the term "research-grade P7C3-A20 inhibitor" or "supplement." It is vital to distin P7C3-A20 treats traumatic brain injury in rats by guish between legitimate chemical suppliers and consumer-grade products. High-quality samples, typically verified by HPLC purity (often >99%), are the standard for epigenetic studies and cancer research.

The distinction between P7C3 and A20 is also important for researchers. While P7C3 is the parent compound, A20 is considered a more stable and effective derivative. For those interested in the technical specifications, the molecular weight is 506.21, and the CAS number is 1235481-90-9.

Conclusion

The body of research surrounding P7C3-A20 is vast and continues to grow. From helping to reduce neurological deficits in traumatic brain injury models to its potential in addressing complex neurodegenerative pathologies, the compound remains a cornerstone of current laboratory investigation. As we look toward the future, the ability of this substance to promote endogenous reparative strategies remains one of the most promising avenues for understanding how we might one day support the delicate architecture of the brain.

*Disclaimer: This content is for informational and educational purposes only. It is not intended to provide medical advice, diagnosis, or treatment for any human condition.*

Leave a Comment
Get new articles in your inbox

News, updates and freebies. No spam, unsubscribe anytime.